THR-317 8mg

DRUG2 trials

Sponsors

Oxurion, ThromboGenics

Conditions

Diabetes MellitusDiabetic RetinopathyIdiopathic Juxtafoveal Retinal TelangiectasiaMacular EdemaRetinal Telangiectasis

Phase 2

A Study to Evaluate THR-317 and Ranibizumab Combination Treatment for Diabetic Macular Oedema (DME)

CompletedNCT03499223

OxurionDiabetes Mellitus, Diabetic Retinopathy, Macular Edema

Start: 2018-04-20End: 2019-07-18Updated: 2019-08-02

A Study to Evaluate THR-317 Treatment for Macular Telangiectasia Type 1 (MacTel 1)

CompletedNCT03669393

ThromboGenicsIdiopathic Juxtafoveal Retinal Telangiectasia, Retinal Telangiectasis

Start: 2018-09-18End: 2019-11-22Updated: 2020-09-02